IMMUTEP LIMITED — Board/Management Information 2022

Feb 1, 2022

ASX/Media Release

Passing of Grant Chamberlain, Non-Executive Director

SYDNEY, AUSTRALIA – 2 February 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) regrettably announces that Non-Executive Director Grant Chamberlain passed away suddenly and unexpectedly on 28 January 2022.

'We are shocked and deeply saddened by Grant’s unexpected passing. He was a very well respected and much liked member of the Immutep team. Serving on our Board since August 2017, it was an honour to work closely with him and to know him personally. We will all miss his lively presence, his passion for Immutep and his extensive corporate and financial insights,' said Chairman, Russell Howard.

The Board and staff of Immutep would like to extend their sincere condolences to Grant’s family and friends.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by the Board of Immutep Limited.

Immutep Limited , Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia ABN: 90 009 237 889

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity IMMUTEP LIMITED (ASX:IMM) ABN 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Mr Grant Chamberlain
Date of last notice	4 October 2021
Date that director ceased to be director	28 January 2022

Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

==> picture [21 x 10] intentionally omitted <==

----- Start of picture text ----- N/A----- End of picture text -----

• See chapter 19 for defined terms.

11/3/2002

Appendix 3Z Page 1

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances giving riseto the relevant interestSinging Frog Pty Ltd (as trustee forthe Chamberlain and Scott FamilyTrust).	Number & class of securities1.2,178,023 Fully Paid OrdinaryShares2.900,000 Performance Rights

Part 3 – Director’s interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
No. and class of securities to whichinterest relates	N/A

• See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002